Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

AstraZeneca takeover: Cameron 'must intervene' in Pfizer's bid

 

Friday 16 May 2014 13:11 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

David Cameron has come under renewed pressure to intervene in Pfizer’s £63 billion takeover bid for AstraZeneca after Swedish ministers said it was important for the UK to influence the “semi-hostile” approach.

The comments came as Astra’s chief executive Pascal Soriot told the London Evening Standard that “a merger could be disruptive” to potential new cancer medicine breakthroughs, adding: “There is no amount of ring-fencing [of research] you can do to address that.”

Sweden’s finance minister Anders Borg and enterprise minister, Annie Lööf, similarly warned that Pfizer’s potential takeover was “not in the interest of important life-science research in Sweden, in the UK or elsewhere.”

The ministers wrote in the Wall Street Journal that Pfizer’s jobs guarantees in its “semi-hostile” takeover “do not seem to be sufficient.”

They added: “Pfizer has a history of quickly and sharply cutting staff in the wake of acquisitions” and said nearly 100,000 employees had been sacked by the US giant since 1999.

They concluded: “AstraZeneca’s owners should seriously consider rejecting Pfizer’s proposal.”

AstraZeneca has some 5900 employees in Sweden and has become the nation’s top corporate taxpayer since the country’s Astra merged with Zeneca of the UK 15 years ago.

A deal by Pfizer, which is expected to table an improved bid within days, would be the biggest foreign takeover in British history, but David Cameron has indicated his confidence in Pfizer’s jobs pledges, such as a fifth of the combined drugmaker’s research roles being in the UK for the next five years, means he will take a hands-off approach to any bid.

He added: “Britain benefits massively by being an economy that is open to overseas investment.”

Soriot, who is today visiting more investors to build up support for independence, maintained “this deal is not inevitable”, elaborating that a “lot of people think this is a done deal and a question of price [but] we are actually very confident we can create shareholder value on our own”.

It has emerged that Pfizer chief Ian Read and top scientist Mikael Dolsten sold more than $12 million (£7 million) of their shares in the drugmaker just two months ago, The Independent revealed.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in